精神分裂症、双相障碍和重性抑郁障碍患者COVID-19感染、住院和死亡差异:英国生物银行队列研究
基于英国生物银行447,296名参与者的队列研究,分析了精神分裂症/精神病性障碍、双相障碍和重性抑郁障碍患者COVID-19感染、住院和死亡风险。未调整分析中三类患者死亡OR分别为4.84、3.76和1.99;完全调整后死亡和住院风险仍显著升高,感染风险仅重性抑郁障碍显著升高。作者建议优先为这些脆弱群体接种疫苗和采取预防措施。
要点
- 精神分裂症/精神病性障碍、双相障碍和重性抑郁障碍患者COVID-19死亡、住院和感染风险均升高。
- 完全调整混杂因素后,死亡和住院风险仍显著升高,感染风险仅重性抑郁障碍显著。
- 仅部分差异可由既有人口学特征或共病解释,作者建议优先为这些群体接种疫苗和预防。
核心结论
- 精神分裂症/精神病性障碍、双相障碍和重性抑郁障碍患者COVID-19感染、住院和死亡风险更高,仅部分差异由既有人口学特征或共病解释,作者建议优先为这些脆弱群体接种疫苗和采取预防措施。
研究设计与样本
- 英国生物银行队列研究,纳入447,296名参与者(精神分裂症/精神病性障碍1925例、双相障碍1483例、重性抑郁障碍41,448例、无重性精神疾病402,440例),链接医疗和死亡记录,采用多变量 logistic 回归分析按诊断比较COVID-19结局,控制社会人口学因素和共病。
主要发现
- 未调整分析中,与无重性精神疾病者相比,精神分裂症/精神病性障碍患者COVID-19死亡OR为4.84(95%CI 3.00-7.34),双相障碍OR为3.76(95%CI 2.00-6.35),重性抑郁障碍OR为1.99(95%CI 1.69-2.33)。
- 未调整分析中,精神分裂症/精神病性障碍患者感染OR为1.61(95%CI 1.32-1.96)、住院OR为3.47(95%CI 2.47-4.72);双相障碍患者感染OR为1.48(95%CI 1.16-1.85)、住院OR为3.31(95%CI 2.22-4.73)。
- 完全调整模型中,所有重性精神疾病组的死亡和住院OR仍显著升高,感染OR仅重性抑郁障碍组仍显著升高。
关键数值与推荐
- 未调整分析中,精神分裂症/精神病性障碍患者COVID-19死亡OR为4.84(95%CI 3.00-7.34),双相障碍OR为3.76(95%CI 2.00-6.35),重性抑郁障碍OR为1.99(95%CI 1.69-2.33),均以无重性精神疾病者为参照。
- 未调整分析中,精神分裂症/精神病性障碍患者感染OR为1.61(95%CI 1.32-1.96)、住院OR为3.47(95%CI 2.47-4.72),双相障碍患者感染OR为1.48(95%CI 1.16-1.85)、住院OR为3.31(95%CI 2.22-4.73)。
临床怎么用
- 作者建议在这些特别脆弱的群体中优先接种疫苗和采取预防措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
People with severe mental illness (SMI; including schizophrenia/psychosis, bipolar disorder (BD), major depressive disorder (MDD)) experience large disparities in physical health. Emerging evidence suggests this group experiences higher risks of infection and death from COVID-19, although the full extent of these disparities are not yet established. We investigated COVID-19 related infection, hospitalisation and mortality among people with SMI in the UK Biobank (UKB) cohort study. Overall, 447,296 participants from UKB (schizophrenia/psychosis = 1925, BD = 1483 and MDD = 41,448, non-SMI = 402,440) were linked with healthcare and death records. Multivariable logistic regression analysis was used to examine differences in COVID-19 outcomes by diagnosis, controlling for sociodemographic factors and comorbidities. In unadjusted analyses, higher odds of COVID-19 mortality were seen among people with schizophrenia/psychosis (odds ratio [OR] 4.84, 95% confidence interval [CI] 3.00-7.34), BD (OR 3.76, 95% CI 2.00-6.35), and MDD (OR 1.99, 95% CI 1.69-2.33) compared to people with no SMI. Higher odds of infection and hospitalisation were also seen across all SMI groups, particularly among people with schizophrenia/psychosis (OR 1.61, 95% CI 1.32-1.96; OR 3.47, 95% CI 2.47-4.72) and BD (OR 1.48, 95% CI 1.16-1.85; OR 3.31, 95% CI 2.22-4.73). In fully adjusted models, mortality and hospitalisation odds remained significantly higher among all SMI groups, though infection odds remained significantly higher only for MDD. People with schizophrenia/psychosis, BD and MDD have higher risks of COVID-19 infection, hospitalisation and mortality. Only a proportion of these disparities were accounted for by pre-existing demographic characteristics or comorbidities. Vaccination and preventive measures should be prioritised in these particularly vulnerable groups.
引用
- Hassan L, Peek N, Lovell K, et al. Disparities in COVID-19 infection, hospitalisation and death in people with schizophrenia, bipolar disorder, and major depressive disorder: a cohort study of the UK Biobank. Mol Psychiatry. 2021. PMID: 34873324. doi:10.1038/s41380-021-01344-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。